Key facts
- This page summarizes Helen Susan Kim's Form 4 filing for Aktis Oncology, Inc. (AKTS).
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 12 Jan 2026, 17:00.
Helen Susan Kim - 12 Jan 2026 Form 4 Insider Report for Aktis Oncology, Inc. (AKTS)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- AKTS
- Reported as of
- 12 Jan 2026
- Net transaction value
- +$15,030,000
- SEC form
- 4
- Accepted by SEC
- 12 Jan 2026, 17:00:10 UTC
- Prior SEC filing
- 08 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Karen McCarthy, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Helen Susan Kim filed Form 4 for Aktis Oncology, Inc. (AKTS) on 12 Jan 2026.
Change
- Previous filing in this sequence was filed on 08 Jan 2026.
- Current net transaction value: +$15,030,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001422772
Primary reporting owner
Kim Helen Susan
- Relationship
- Director, 10%+ Owner
- Address
- C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON
- Signature
- /s/ Karen McCarthy, as Attorney-in-Fact
- Signature date
- 12 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKTS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +4,859,370
- Change %
- Price
- Shares after
- 4,859,370
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F1, F2
AKTS
transaction
Common Stock
Purchase
- Transaction value
- $14,624,190
- Shares
- +812,455
- Change %
- +17%
- Price
- $18.00
- Shares after
- 5,671,825
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F2
AKTS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +134,842
- Change %
- Price
- Shares after
- 134,842
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F1, F3
AKTS
transaction
Common Stock
Purchase
- Transaction value
- $405,810
- Shares
- +22,545
- Change %
- +17%
- Price
- $18.00
- Shares after
- 157,387
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKTS
transaction
Derivative
Series A Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -14,838,250
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,900,284
- Exercise price
- Footnotes
- F2, F4
AKTS
transaction
Derivative
Series A Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -411,750
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 108,229
- Exercise price
- Footnotes
- F3, F4
AKTS
transaction
Derivative
Series B Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -3,648,750
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 959,086
- Exercise price
- Footnotes
- F2, F5
AKTS
transaction
Derivative
Series B Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -101,250
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 26,613
- Exercise price
- Footnotes
- F3, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration.
Footnote F2
These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
Footnote F3
These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
Footnote F4
The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.
Footnote F5
The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.